WELL Health Technologies Corp.

DB:W7V Stock Report

Market Cap: €1.2b

WELL Health Technologies Valuation

Is W7V undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of W7V when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€20.69
Fair Value
78.0% undervalued intrinsic discount
15
Number of Analysts

Below Fair Value: W7V (€4.55) is trading below our estimate of fair value (€20.69)

Significantly Below Fair Value: W7V is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for W7V?

Key metric: As W7V is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for W7V. This is calculated by dividing W7V's market cap by their current earnings.
What is W7V's PE Ratio?
PE Ratio23.2x
EarningsCA$73.43m
Market CapCA$1.72b

Price to Earnings Ratio vs Peers

How does W7V's PE Ratio compare to its peers?

The above table shows the PE ratio for W7V vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.5x
SYAB SYNLAB
27.7x-11.4%€2.5b
V3V VITA 34
27.8x-25.4%€71.8m
FME Fresenius Medical Care
19.4x16.9%€12.8b
RHK RHÖN-KLINIKUM
23.1x7.5%€1.0b
W7V WELL Health Technologies
23.2x-10.6%€1.7b

Price-To-Earnings vs Peers: W7V is good value based on its Price-To-Earnings Ratio (23.2x) compared to the peer average (24.5x).


Price to Earnings Ratio vs Industry

How does W7V's PE Ratio compare vs other companies in the European Healthcare Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
W7V 23.2xIndustry Avg. 18.8xNo. of Companies8PE01020304050+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: W7V is expensive based on its Price-To-Earnings Ratio (23.2x) compared to the European Healthcare industry average (18.8x).


Price to Earnings Ratio vs Fair Ratio

What is W7V's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

W7V PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio23.2x
Fair PE Ratio14.9x

Price-To-Earnings vs Fair Ratio: W7V is expensive based on its Price-To-Earnings Ratio (23.2x) compared to the estimated Fair Price-To-Earnings Ratio (14.9x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst W7V forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€4.55
€5.81
+27.8%
13.3%€7.40€4.71n/a15
Jan ’26€4.57
€5.70
+24.8%
14.3%€7.35€4.67n/a15
Dec ’25€3.64
€5.15
+41.4%
19.5%€6.71€3.52n/a15
Nov ’25€2.84
€4.99
+75.8%
19.8%€6.61€3.31n/a15
Oct ’25€2.86
€5.02
+75.7%
19.6%€6.59€3.30n/a15
Sep ’25€2.94
€5.02
+70.8%
19.6%€6.59€3.30n/a15
Aug ’25€3.14
€5.10
+62.2%
21.3%€6.78€3.22n/a14
Jul ’25€3.15
€5.14
+63.1%
21.3%€6.83€3.25n/a14
Jun ’25€2.42
€5.03
+108.2%
20.8%€6.75€3.21n/a15
May ’25€2.39
€5.06
+111.8%
20.5%€6.84€3.25n/a16
Apr ’25€2.52
€5.06
+100.9%
22.0%€7.47€3.23n/a16
Mar ’25€2.71
€5.13
+89.3%
22.2%€7.58€3.28n/a17
Feb ’25€2.57
€5.29
+106.3%
22.5%€7.57€3.27n/a16
Jan ’25€2.61
€5.33
+104.1%
20.4%€7.45€3.56€4.5715
Dec ’24€2.66
€5.33
+100.6%
20.4%€7.45€3.56€3.6415
Nov ’24€2.51
€5.58
+122.3%
19.9%€8.15€3.74€2.8414
Oct ’24€2.97
€5.58
+87.9%
19.9%€8.15€3.74€2.8614
Sep ’24€3.14
€5.58
+77.7%
19.9%€8.15€3.74€2.9414
Aug ’24€3.13
€5.63
+79.9%
22.7%€9.15€3.73€3.1414
Jul ’24€3.20
€5.72
+78.9%
23.3%€9.41€3.84€3.1514
Jun ’24€3.41
€5.65
+65.8%
22.5%€9.24€3.76€2.4215
May ’24€3.59
€5.35
+49.2%
25.0%€9.03€3.34€2.3914
Apr ’24€3.14
€5.34
+70.3%
26.0%€9.05€3.35€2.5213
Mar ’24€3.01
€5.43
+80.3%
27.0%€9.37€3.47€2.7113
Feb ’24€2.41
€5.30
+120.3%
26.9%€9.29€3.44€2.5714
Jan ’24€1.90
€5.57
+193.1%
27.1%€9.81€3.63€2.6114
Analyst Price Target
Consensus Narrative from 15 Analysts
€5.74
Fair Value
20.8% undervalued intrinsic discount
15
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/09 01:41
End of Day Share Price 2025/01/09 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

WELL Health Technologies Corp. is covered by 25 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gabriel LeungBeacon Securities Limited
Douglas TaylorCanaccord Genuity
Scott FletcherCIBC Capital Markets